Ajanta Pharma shares move up over 3% on USFDA nod for drug

Shares of Ajanta Pharma rose over 3 per cent today as the company received nod from US health regulator for generic Omeprazole and sodium bicarbonate powder for oral suspension used for treatment of stomach and esophagus problems such as ulcers and acid reflux.
The scrip went up by 2.99 per cent to settle at Rs 1,777.20 on BSE. During the day, it rose 3.44 per cent to Rs 1,785.
On NSE, the company jumped 3.35 per cent to close at Rs 1,781.65.
The company has received approval from the United States Food and Drug Administration (USFDA) for the product and will soon be launching the same, Ajanta Pharma said in a BSE filing.

The launch will be in two strengths, 20 mg/1,680 mg and 40 mg/1,680 mg powder sachets, it added.
This new approval is part of portfolio of products that the company has developed for the US market, it added.